Paul van der Horst is Chief Business Officer at Agomab Therapeutics, Belgium, where he leads the corporate development, procurement, IP and QA functions. Prior to Agomab, he was Head of Corporate Development at Galapagos NV (Euronext, NASDAQ: GLPG) from 2016-2021. In this role, he led all major transactions, investments, licensing, and M&A activities. From 2013-2016, he worked at boutique investment bank Kempen & Co in Amsterdam, where he was responsible for broking and trading of European pharma & biotech stocks to institutional investors in Europe and the US. In his career, Paul has been the lead negotiator and deal lead in over 20 pharmaceutical licensing and M&A transactions and has raised over USD2bn through equity capital market transactions. Paul is the President of the Board of Directors at Molecure (WSE: MOC, Warsaw, Poland) and has been an advisor and non-executive board member at ImmuneTune The Netherlands) and Fibrocor Therapeutics (Toronto, Canada). Dr. van der Horst studied medicine and holds a Ph.D. in Gynecology from the Erasmus University Medical Center in Rotterdam, The Netherlands.